<p>Centessa Pharmaceuticals PLC 赞助的 ADR（NASDAQ:CNTA - 获取免费报告）已获得目前覆盖该股票的十二家研究公司的共识推荐为 “适度买入”，Marketbeat 报道。一位投资分析师对该股票给予了卖出评级，十位分析师给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪公司平均 12 个月目标价为 33.1111 美元。</p>
<ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
<p>多家股票分析师对 CNTA 股票进行了评论。Guggenheim 在 10 月 6 日的报告中重申了 “买入” 评级，并将 Centessa Pharmaceuticals 的目标价设定为 28.00 美元。Truist Financial 在 11 月 5 日的研究报告中将 Centessa Pharmaceuticals 的目标价设定为 30.00 美元。华尔街禅在 10 月 27 日的报告中将 Centessa Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。Stephens 在 10 月 28 日的研究报告中开始覆盖 Centessa Pharmaceuticals 的股票。他们给予了 “增持” 评级，并为该公司设定了 35.00 美元的目标价。最后，Chardan Capital 在 8 月 12 日的研究报告中重申了 “买入” 评级，并为 Centessa Pharmaceuticals 的股票设定了 30.00 美元的目标价。</p>
<p><strong>阅读我们关于 Centessa Pharmaceuticals 的最新股票分析</strong></p>
<h2>Centessa Pharmaceuticals 的内部交易</h2>
<p>在其他新闻中，内部人士 Mario Alberto Accardi 于 9 月 16 日星期二出售了 8,172 股公司的股票。该股票以平均价格 21.40 美元出售，总价值为 174,880.80 美元。出售完成后，该内部人士直接持有 197,394 股公司的股票，价值为 4,224,231.60 美元。这代表了他们持股比例的 3.98% 的下降。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。此外，首席技术官 Tia L. Bush 于 11 月 12 日星期三出售了 40,000 股股票。该股票以平均价格 26.00 美元出售，总价值为 1,040,000.00 美元。出售完成后，首席技术官直接持有 121,503 股公司的股票，价值约为 3,159,078 美元。这代表了他们持股比例的 24.77% 的下降。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士总共出售了价值 4,106,481 美元的 179,964 股公司股票。内部人士持有公司股票的 7.09%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近修改了对公司的持股。Caitong International Asset Management Co. Ltd 在第一季度将其在 Centessa Pharmaceuticals 的股份增加了 15,209.5%。Caitong International Asset Management Co. Ltd 现在拥有 3,215 股公司的股票，价值 46,000 美元，此前在该期间又购买了 3,194 股。Osterweis Capital Management Inc. 在第一季度购买了 Centessa Pharmaceuticals 的新股份，价值约为 47,000 美元。纽约梅隆银行在第一季度获得了 Centessa Pharmaceuticals 的新职位，价值约为 147,000 美元。Fox Run Management L.L.C. 在第一季度购买了 Centessa Pharmaceuticals 的新职位，价值约为 160,000 美元。最后，Vestal Point Capital LP 在第一季度获得了 Centessa Pharmaceuticals 的新股份，价值 214,000 美元。机构投资者和对冲基金持有公司股票的 82.01%。</p>
<h2>Centessa Pharmaceuticals 股票下跌 1.1%</h2>
<p>NASDAQ CNTA 的股票在星期二开盘价为 27.32 美元。该公司的市值为 36.7 亿美元，市盈率为-14.93，贝塔系数为 1.56。公司的 50 日简单移动平均为 23.36 美元，200 日简单移动平均为 17.65 美元。公司的速动比率为 10.57，流动比率为 10.56，债务股本比率为 0.36。Centessa Pharmaceuticals 的 52 周低点为 9.60 美元，52 周高点为 29.29 美元。</p>
<p>Centessa Pharmaceuticals（NASDAQ:CNTA - 获取免费报告）最后一次发布季度财报是在 11 月 5 日星期三。该公司报告的每股收益为（0.41 美元），低于共识预期的（0.39 美元）0.02 美元。股票分析师预测 Centessa Pharmaceuticals 本财年的每股收益为-1.6。</p>
<h2>Centessa Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于为患者发现、开发和提供药物。其产品管线包括 SerpinPC，一种用于治疗 A 型和 B 型血友病的活化蛋白 C 抑制剂；以及 ORX750，一种用于治疗嗜睡症和其他睡眠障碍的口服 OX2R 激动剂。</p>
<h2>精选故事</h2>
<ul>
<li>我们更喜欢的五只股票超过 Centessa Pharmaceuticals</li>
<li>市值计算器：如何计算市值</li>
<li>惠而浦的最糟糕时期可能已经过去——未来有上涨机会</li>
<li>什么是日经 225 指数？</li>
<li>这三只被打压的股票可能是你本季度最佳的购买机会</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>D-Wave 在财报季后与量子竞争对手相比如何？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
<p>在考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Centessa Pharmaceuticals 并不在名单上。</p>
<p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CNTA

<p>Centessa Pharmaceuticals PLC（纳斯达克代码：CNTA）获得了十二家研究公司的 “适度买入” 共识评级。分析师设定的 12 个月平均目标价为 33.11 美元。最近的内部交易包括 Mario Alberto Accardi 和首席技术官 Tia L. Bush 的股票出售。机构投资者持有该公司 82.01% 的股份。Centessa Pharmaceuticals 报告的季度每股亏损为 0.41 美元，低于预期 0.02 美元</p>

<p>Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) have received a consensus recommendation of &#34;Moderate Buy&#34; from the twelve research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $33.1111.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals PLC 赞助的 ADR（NASDAQ:CNTA - 获取免费报告）已获得目前覆盖该股票的十二家研究公司的共识推荐为 “适度买入”，Marketbeat 报道。一位投资分析师对该股票给予了卖出评级，十位分析师给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪公司平均 12 个月目标价为 33.1111 美元。</p>
</div><ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
</div><p>A number of equities analysts have commented on CNTA shares. Guggenheim reissued a &#34;buy&#34; rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Truist Financial set a $30.00 price target on Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Wall Street Zen upgraded Centessa Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 27th. Stephens began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They issued an &#34;overweight&#34; rating and a $35.00 target price for the company. Finally, Chardan Capital reissued a &#34;buy&#34; rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th.</p>
<div class="lb-trans"><p>多家股票分析师对 CNTA 股票进行了评论。Guggenheim 在 10 月 6 日的报告中重申了 “买入” 评级，并将 Centessa Pharmaceuticals 的目标价设定为 28.00 美元。Truist Financial 在 11 月 5 日的研究报告中将 Centessa Pharmaceuticals 的目标价设定为 30.00 美元。华尔街禅在 10 月 27 日的报告中将 Centessa Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。Stephens 在 10 月 28 日的研究报告中开始覆盖 Centessa Pharmaceuticals 的股票。他们给予了 “增持” 评级，并为该公司设定了 35.00 美元的目标价。最后，Chardan Capital 在 8 月 12 日的研究报告中重申了 “买入” 评级，并为 Centessa Pharmaceuticals 的股票设定了 30.00 美元的目标价。</p>
</div><p><strong>Read Our Latest Stock Analysis on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Centessa Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Insider Transactions at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的内部交易</h2>
</div><p>In other news, insider Mario Alberto Accardi sold 8,172 shares of the company's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total value of $174,880.80. Following the completion of the sale, the insider directly owned 197,394 shares in the company, valued at $4,224,231.60. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares of the company's stock, valued at approximately $3,159,078. This represents a 24.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 179,964 shares of company stock worth $4,106,481 in the last ninety days. Insiders own 7.09% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Mario Alberto Accardi 于 9 月 16 日星期二出售了 8,172 股公司的股票。该股票以平均价格 21.40 美元出售，总价值为 174,880.80 美元。出售完成后，该内部人士直接持有 197,394 股公司的股票，价值为 4,224,231.60 美元。这代表了他们持股比例的 3.98% 的下降。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。此外，首席技术官 Tia L. Bush 于 11 月 12 日星期三出售了 40,000 股股票。该股票以平均价格 26.00 美元出售，总价值为 1,040,000.00 美元。出售完成后，首席技术官直接持有 121,503 股公司的股票，价值约为 3,159,078 美元。这代表了他们持股比例的 24.77% 的下降。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士总共出售了价值 4,106,481 美元的 179,964 股公司股票。内部人士持有公司股票的 7.09%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its stake in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the period. Osterweis Capital Management Inc. purchased a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at approximately $47,000. Bank of New York Mellon Corp acquired a new position in Centessa Pharmaceuticals in the first quarter valued at approximately $147,000. Fox Run Management L.L.C. purchased a new position in Centessa Pharmaceuticals in the first quarter worth approximately $160,000. Finally, Vestal Point Capital LP acquired a new stake in Centessa Pharmaceuticals during the first quarter worth $214,000. Institutional investors and hedge funds own 82.01% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近修改了对公司的持股。Caitong International Asset Management Co. Ltd 在第一季度将其在 Centessa Pharmaceuticals 的股份增加了 15,209.5%。Caitong International Asset Management Co. Ltd 现在拥有 3,215 股公司的股票，价值 46,000 美元，此前在该期间又购买了 3,194 股。Osterweis Capital Management Inc. 在第一季度购买了 Centessa Pharmaceuticals 的新股份，价值约为 47,000 美元。纽约梅隆银行在第一季度获得了 Centessa Pharmaceuticals 的新职位，价值约为 147,000 美元。Fox Run Management L.L.C. 在第一季度购买了 Centessa Pharmaceuticals 的新职位，价值约为 160,000 美元。最后，Vestal Point Capital LP 在第一季度获得了 Centessa Pharmaceuticals 的新股份，价值 214,000 美元。机构投资者和对冲基金持有公司股票的 82.01%。</p>
</div><h2>Centessa Pharmaceuticals Stock Down 1.1%</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股票下跌 1.1%</h2>
</div><p>Shares of NASDAQ CNTA opened at $27.32 on Tuesday. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -14.93 and a beta of 1.56. The company's 50-day simple moving average is $23.36 and its 200-day simple moving average is $17.65. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $29.29.</p>
<div class="lb-trans"><p>NASDAQ CNTA 的股票在星期二开盘价为 27.32 美元。该公司的市值为 36.7 亿美元，市盈率为-14.93，贝塔系数为 1.56。公司的 50 日简单移动平均为 23.36 美元，200 日简单移动平均为 17.65 美元。公司的速动比率为 10.57，流动比率为 10.56，债务股本比率为 0.36。Centessa Pharmaceuticals 的 52 周低点为 9.60 美元，52 周高点为 29.29 美元。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（NASDAQ:CNTA - 获取免费报告）最后一次发布季度财报是在 11 月 5 日星期三。该公司报告的每股收益为（0.41 美元），低于共识预期的（0.39 美元）0.02 美元。股票分析师预测 Centessa Pharmaceuticals 本财年的每股收益为-1.6。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于为患者发现、开发和提供药物。其产品管线包括 SerpinPC，一种用于治疗 A 型和 B 型血友病的活化蛋白 C 抑制剂；以及 ORX750，一种用于治疗嗜睡症和其他睡眠障碍的口服 OX2R 激动剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Whirlpool’s Worst May Be Over—Upside Opportunity Ahead</li>
<li>What is the Nikkei 225 index?</li>
<li>These 3 Beaten-Down Stocks Could Be Your Best Buying Opportunity This Quarter</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>How Does D-Wave Stack Up to Quantum Rivals After Earnings Season?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Centessa Pharmaceuticals</li>
<li>市值计算器：如何计算市值</li>
<li>惠而浦的最糟糕时期可能已经过去——未来有上涨机会</li>
<li>什么是日经 225 指数？</li>
<li>这三只被打压的股票可能是你本季度最佳的购买机会</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>D-Wave 在财报季后与量子竞争对手相比如何？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Centessa Pharmaceuticals 并不在名单上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Centessa Pharmaceuticals PLC 赞助的美国存托凭证（NASDAQ:CNTA）获得分析师一致评级为 “适度买入”